At the news
? NEUTRALIMPACT 3/10 144 filed Nov 4, 2026 at 16:30 ET
CEO Daniel O'Day filed a Form 144 notice to sell 112,429 shares of Gilead Sciences common stock, valued at approximately $18.8 million, to be acquired through stock option exercises over the next three months. The filing also discloses prior 10b5-1 plan sales totaling about $9.8 million in the preceding weeks. While the sale is large in absolute terms, it represents a small fraction of the company's $211B market cap and appears to be part of a pre-arranged trading plan.
- CEO Daniel O'Day filed Form 144 to sell 112,429 shares of common stock
- Estimated aggregate value of proposed sale: $18,828,484.63
- Shares to be acquired via exercise of stock options over the next three months
- Prior 10b5-1 plan sales disclosed: 15,000 shares on 11/02/2026 ($2.55M), 15,881 shares on 10/30/2026 ($2.78M), 15,000 shares on 10/01/2026 ($2.22M), 15,000 shares on 09/01/2026 ($2.23M)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access